Cargando…

Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure

Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Komici, Klara, Gnemmi, Isabella, Bencivenga, Leonardo, Vitale, Dino Franco, Rengo, Giuseppe, Di Stefano, Antonino, Eleuteri, Ermanno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408835/
https://www.ncbi.nlm.nih.gov/pubmed/32674344
http://dx.doi.org/10.3390/jcm9072229
_version_ 1783567924191035392
author Komici, Klara
Gnemmi, Isabella
Bencivenga, Leonardo
Vitale, Dino Franco
Rengo, Giuseppe
Di Stefano, Antonino
Eleuteri, Ermanno
author_facet Komici, Klara
Gnemmi, Isabella
Bencivenga, Leonardo
Vitale, Dino Franco
Rengo, Giuseppe
Di Stefano, Antonino
Eleuteri, Ermanno
author_sort Komici, Klara
collection PubMed
description Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, exerts a relevant activity in the processes of cardiac inflammation and fibrosis. The aim of the present study was to investigate the potential of Galectin-3 to serve as a biomarker of frailty in HF patients. Methods: 128 consecutive patients aged 65 and older with the diagnosis of systolic HF underwent a frailty assessment and blood sample collection for serum Gal-3 detection. A multivariable regression analysis and decision curve analysis (DCA) were used to identify significant predictors of frailty. Results: Frailty was present in 42.2% of patients. Age: Odds Ratio (OR) = 3.29; 95% Confidence Interval CI (CI) = 1.03–10.55, Cumulative Illness Rating Scale Comorbidity Index (CIRS-CI): OR = 1.85; 95% CI = 1.03–3.32, C-Reactive phase Protein (CRP) OR = 3.73; 95% CI = 1.24–11.22, N-terminal-pro-Brain Natriuretic Peptide (NT-proBNP): OR = 2.39; 95% CI = 1.21–4.72 and Gal-3: OR = 5.64; 95% CI = 1.97–16.22 resulted in being significantly and independently associated with frailty. The DCA demonstrated that the addition of Gal-3 in the prognostic model resulted in an improved clinical ‘net’ benefit. Conclusions: Circulating levels of Gal-3 are independently associated with frailty in elderly patients with systolic HF.
format Online
Article
Text
id pubmed-7408835
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74088352020-08-13 Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure Komici, Klara Gnemmi, Isabella Bencivenga, Leonardo Vitale, Dino Franco Rengo, Giuseppe Di Stefano, Antonino Eleuteri, Ermanno J Clin Med Article Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, exerts a relevant activity in the processes of cardiac inflammation and fibrosis. The aim of the present study was to investigate the potential of Galectin-3 to serve as a biomarker of frailty in HF patients. Methods: 128 consecutive patients aged 65 and older with the diagnosis of systolic HF underwent a frailty assessment and blood sample collection for serum Gal-3 detection. A multivariable regression analysis and decision curve analysis (DCA) were used to identify significant predictors of frailty. Results: Frailty was present in 42.2% of patients. Age: Odds Ratio (OR) = 3.29; 95% Confidence Interval CI (CI) = 1.03–10.55, Cumulative Illness Rating Scale Comorbidity Index (CIRS-CI): OR = 1.85; 95% CI = 1.03–3.32, C-Reactive phase Protein (CRP) OR = 3.73; 95% CI = 1.24–11.22, N-terminal-pro-Brain Natriuretic Peptide (NT-proBNP): OR = 2.39; 95% CI = 1.21–4.72 and Gal-3: OR = 5.64; 95% CI = 1.97–16.22 resulted in being significantly and independently associated with frailty. The DCA demonstrated that the addition of Gal-3 in the prognostic model resulted in an improved clinical ‘net’ benefit. Conclusions: Circulating levels of Gal-3 are independently associated with frailty in elderly patients with systolic HF. MDPI 2020-07-14 /pmc/articles/PMC7408835/ /pubmed/32674344 http://dx.doi.org/10.3390/jcm9072229 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Komici, Klara
Gnemmi, Isabella
Bencivenga, Leonardo
Vitale, Dino Franco
Rengo, Giuseppe
Di Stefano, Antonino
Eleuteri, Ermanno
Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
title Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
title_full Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
title_fullStr Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
title_full_unstemmed Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
title_short Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
title_sort impact of galectin-3 circulating levels on frailty in elderly patients with systolic heart failure
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408835/
https://www.ncbi.nlm.nih.gov/pubmed/32674344
http://dx.doi.org/10.3390/jcm9072229
work_keys_str_mv AT komiciklara impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure
AT gnemmiisabella impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure
AT bencivengaleonardo impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure
AT vitaledinofranco impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure
AT rengogiuseppe impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure
AT distefanoantonino impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure
AT eleuteriermanno impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure